Whittington R, Solin L, Mohiuddin M, Cantor R I, Rosato F E, Biermann W A, Weiss S M, Pajak T F
Cancer. 1984 Nov 1;54(9):1991-8. doi: 10.1002/1097-0142(19841101)54:9<1991::aid-cncr2820540934>3.0.co;2-4.
Eighty-eight patients with localized unresectable carcinoma of the pancreas were treated at Thomas Jefferson University Hospital between 1974 and 1981. Four treatment regimens were used which were sequential modifications of the technique based on the experience in the preceding group of patients. Each treatment changed the course of the disease, and as patterns of failure were identified, the treatment was altered to deal with them. Initially, all patients were treated with external beam radiation. Subsequently, Iodine-125 implantation was added to improve local control; low-dose preoperative radiotherapy to reduce the risk of peritoneal seeding; and adjuvant chemotherapy to reduce the risks of distant metastases. The addition of 125I implantation increased the local control from 22% to 81%, but did not increase the median survival, which was unchanged from 7 months. The addition of adjuvant chemotherapy increased the median survival from 7 months to 14 months, but had no impact on the control of the pancreatic tumor. Adjunctive chemotherapy and low-dose preoperative radiotherapy appear synergistic in reducing the risk of peritoneal seeding. The combination of 125I implantation, external beam radiation, and adjunctive chemotherapy is safe and effective. This regimen produces excellent local control with acceptable morbidity. This regimen produced a 30% survival at 18 months. The patterns of failure among these patients suggest future modifications of the technique.
1974年至1981年间,托马斯·杰斐逊大学医院对88例局部不可切除的胰腺癌患者进行了治疗。采用了四种治疗方案,这些方案是在前一组患者经验的基础上对技术进行的逐步改进。每种治疗方法都改变了疾病的进程,随着失败模式的确定,治疗方法也相应调整以应对这些问题。最初,所有患者均接受外照射放疗。随后,增加了碘-125植入以改善局部控制;采用低剂量术前放疗以降低腹膜种植的风险;并采用辅助化疗以降低远处转移的风险。碘-125植入的加入使局部控制率从22%提高到81%,但并未提高中位生存期,中位生存期仍为7个月,未发生变化。辅助化疗的加入使中位生存期从7个月提高到14个月,但对胰腺肿瘤的控制没有影响。辅助化疗和低剂量术前放疗在降低腹膜种植风险方面似乎具有协同作用。碘-125植入、外照射放疗和辅助化疗的联合使用是安全有效的。该方案能产生良好的局部控制,且发病率可接受。该方案在18个月时的生存率为30%。这些患者的失败模式提示了该技术未来的改进方向。